CO2020012060A2 - Inhibidores de la arginasa - Google Patents

Inhibidores de la arginasa

Info

Publication number
CO2020012060A2
CO2020012060A2 CONC2020/0012060A CO2020012060A CO2020012060A2 CO 2020012060 A2 CO2020012060 A2 CO 2020012060A2 CO 2020012060 A CO2020012060 A CO 2020012060A CO 2020012060 A2 CO2020012060 A2 CO 2020012060A2
Authority
CO
Colombia
Prior art keywords
compounds
arginase inhibitors
arg2
arg1
inhibitors
Prior art date
Application number
CONC2020/0012060A
Other languages
English (en)
Inventor
Corinne Nicole Foley
Rebecca Louise Grange
Tezcan Guney
Jaroslaw Kalisiak
Eric Thomas Newcomb
Anh Thu Tran
Original Assignee
Arcus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcus Biosciences Inc filed Critical Arcus Biosciences Inc
Publication of CO2020012060A2 publication Critical patent/CO2020012060A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof

Abstract

En el presente documento se describen compuestos que son inhibidores de al menos uno de ARG1 y ARG2 y composiciones que contienen los compuestos y métodos para sintetizar los compuestos. En el presente documento también se describe el uso de tales compuestos y composiciones para el tratamiento de una diversidad de enfermedades, trastornos y afecciones, incluidos los trastornos relacionados con el cáncer y con el sistema inmunitario que están mediados, al menos en parte, por ARG1 y ARG2. 84976163v.1
CONC2020/0012060A 2018-03-05 2020-09-29 Inhibidores de la arginasa CO2020012060A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862638412P 2018-03-05 2018-03-05
PCT/US2019/020507 WO2019173188A1 (en) 2018-03-05 2019-03-04 Arginase inhibitors

Publications (1)

Publication Number Publication Date
CO2020012060A2 true CO2020012060A2 (es) 2021-01-18

Family

ID=67847429

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0012060A CO2020012060A2 (es) 2018-03-05 2020-09-29 Inhibidores de la arginasa

Country Status (19)

Country Link
US (1) US20210002306A1 (es)
EP (1) EP3761992A4 (es)
JP (1) JP7402167B2 (es)
KR (1) KR102656571B1 (es)
CN (1) CN111818928A (es)
AU (1) AU2019229978A1 (es)
BR (1) BR112020017604A2 (es)
CA (1) CA3091805A1 (es)
CL (1) CL2020002271A1 (es)
CO (1) CO2020012060A2 (es)
CR (1) CR20200445A (es)
EA (1) EA202092086A1 (es)
IL (1) IL276813A (es)
MX (1) MX2020009290A (es)
PE (1) PE20210452A1 (es)
PH (1) PH12020551352A1 (es)
SG (1) SG11202008113RA (es)
UA (1) UA127897C2 (es)
WO (1) WO2019173188A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018227187A1 (en) * 2017-06-09 2018-12-13 The Regents Of The University Of California Catheter injectable cyclic peptide pro-gelators for myocardial tissue engineering
EP3810615A4 (en) * 2018-06-20 2022-03-30 Merck Sharp & Dohme Corp. ARGINASE INHIBITORS AND METHODS OF USE
WO2021257643A1 (en) 2020-06-17 2021-12-23 Arcus Biosciences, Inc. Crystalline forms of a cd73 inhibitor and uses thereof
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
US20230159466A1 (en) 2021-10-29 2023-05-25 Arcus Biosciences, Inc. Inhibitors of hif-2alpha and methods of use thereof
WO2023215719A1 (en) 2022-05-02 2023-11-09 Arcus Biosciences, Inc. Anti-tigit antibodies and uses of the same
WO2024015251A1 (en) 2022-07-15 2024-01-18 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
WO2024020034A1 (en) 2022-07-20 2024-01-25 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2024059142A1 (en) 2022-09-14 2024-03-21 Arcus Biosciences, Inc. Dispersions of etrumadenant
WO2024081385A1 (en) 2022-10-14 2024-04-18 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof
WO2024086718A1 (en) 2022-10-20 2024-04-25 Arcus Biosciences, Inc. Lyophilized formulations of cd73 compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3719024A1 (en) 2010-10-26 2020-10-07 Mars, Incorporated Arginase inhibitors as therapeutics
WO2016100555A1 (en) * 2014-12-18 2016-06-23 Inception 4, Inc. Boronic acid derivatives and uses thereof
EP3313410A4 (en) 2015-06-23 2019-01-02 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
PL417066A1 (pl) * 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne

Also Published As

Publication number Publication date
JP7402167B2 (ja) 2023-12-20
US20210002306A1 (en) 2021-01-07
UA127897C2 (uk) 2024-02-07
BR112020017604A2 (pt) 2020-12-22
CA3091805A1 (en) 2019-09-12
MX2020009290A (es) 2020-09-28
WO2019173188A1 (en) 2019-09-12
SG11202008113RA (en) 2020-09-29
PE20210452A1 (es) 2021-03-08
PH12020551352A1 (en) 2021-06-21
EA202092086A1 (ru) 2021-02-09
EP3761992A4 (en) 2021-11-24
KR102656571B1 (ko) 2024-04-11
CR20200445A (es) 2021-04-27
EP3761992A1 (en) 2021-01-13
JP2021516237A (ja) 2021-07-01
IL276813A (en) 2020-10-29
CN111818928A (zh) 2020-10-23
AU2019229978A1 (en) 2020-10-15
KR20200128117A (ko) 2020-11-11
CL2020002271A1 (es) 2021-04-09

Similar Documents

Publication Publication Date Title
CO2020012060A2 (es) Inhibidores de la arginasa
UY38476A (es) Inhibidores de arg1 y/o arg2
PH12021500014A1 (en) Fused ring compounds
PH12021551065A1 (en) Fused ring compounds
CL2017001124A1 (es) Agentes inmunomoduladores
CO2019007863A2 (es) Derivados de benzooxazol como inmunomoduladores
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CL2019000815A1 (es) Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2. (divisional solicitud 201802928).
PH12020550523A1 (en) Modulators of the integrated stress pathway
PH12018502329A1 (en) Modulators of the integrated stress pathway
AU2017261336A1 (en) Modulators of the integrated stress pathway
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
DOP2022000194A (es) Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa
AU2017260374A1 (en) Modulators of the integrated stress pathway
MX2021013193A (es) Cicloalquilos sustituidos como moduladores de la vía integrada del estrés.
UY37098A (es) Moduladores de ror-gamma
BR112017009671A2 (pt) inibidores de ezh2 e usos destes
CR20230182A (es) MODULADORES DE PROFÁRMACOS DE LA VÍA DE ESTRÉS INTEGRADA (Divisional Expediente 2021-238)
EA201890858A1 (ru) 2,4-дигидроксиникотинамиды как агонисты apj
CO2022001210A2 (es) Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes
MX2018013164A (es) Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.
CO2021009129A2 (es) Tubulisinas y conjugados de proteína-tubulisina
ECSP21003171A (es) Dinucleótidos cíclicos como agonistas de sting
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
BR112022000855A2 (pt) Moduladores de nlrp3